Millennium Management’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.01M | Buy |
107,800
+70,735
| +191% | +$596K | ﹤0.01% | 4385 |
|
|
2025
Q4 | $302K | Sell |
37,065
-99,364
| -73% | -$1.23M | ﹤0.01% | 5262 |
|
|
2025
Q3 | $1.73M | Sell |
136,429
-22,733
| -14% | -$216K | ﹤0.01% | 4195 |
|
|
2025
Q2 | $1.1M | Buy |
159,162
+57,555
| +57% | +$418K | ﹤0.01% | 4337 |
|
|
2025
Q1 | $540K | Sell |
101,607
-285,046
| -74% | -$2.52M | ﹤0.01% | 4760 |
|
|
2024
Q4 | $4.56M | Buy |
386,653
+283,902
| +276% | +$4.76M | ﹤0.01% | 2893 |
|
|
2024
Q3 | $2.12M | Sell |
102,751
-138,898
| -57% | -$7.11M | ﹤0.01% | 3653 |
|
|
2024
Q2 | $10.9M | Sell |
241,649
-83,253
| -26% | -$3.5M | 0.01% | 2009 |
|
|
2024
Q1 | $12.7M | Buy |
+324,902
| New | +$8.01M | 0.01% | 1968 |
|
|
2022
Q4 | – | Sell |
-386
| Closed | -$2K | – | 6626 |
|
|
2022
Q3 | $2K | Sell |
386
-11,245
| -97% | -$79.3K | ﹤0.01% | 6920 |
|
|
2022
Q2 | $88K | Sell |
11,631
-4,837
| -29% | -$46.7K | ﹤0.01% | 5985 |
|
|
2022
Q1 | $263K | Sell |
16,468
-5,922
| -26% | -$78.5K | ﹤0.01% | 5659 |
|
|
2021
Q4 | $414K | Sell |
22,390
-147
| -0.7% | -$3.98K | ﹤0.01% | 5237 |
|
|
2021
Q3 | $690K | Sell |
22,537
-18,896
| -46% | -$745K | ﹤0.01% | 5036 |
|
|
2021
Q2 | $2.27M | Buy |
+41,433
| New | +$2.3M | ﹤0.01% | 3805 |
|
|
2021
Q1 | – | Sell |
-596
| Closed | -$22K | – | 6001 |
|
|
2020
Q4 | $22K | Buy |
+596
| New | +$22.3K | ﹤0.01% | 5129 |
|
|
2020
Q3 | – | Sell |
-16,006
| Closed | -$4.03M | – | 4497 |
|
|
2020
Q2 | $4.03M | Buy |
16,006
+14,799
| +1,226% | +$2.99M | 0.01% | 1964 |
|
|
2020
Q1 | $190K | Buy |
+1,207
| New | +$204K | ﹤0.01% | 3410 |
|
|
2019
Q3 | – | Sell |
-25,135
| Closed | -$5.23M | – | 4219 |
|
|
2019
Q2 | $5.23M | Buy |
25,135
+24,224
| +2,659% | +$5.19M | 0.01% | 1743 |
|
|
2019
Q1 | $190K | Sell |
911
-3,431
| -79% | -$757K | ﹤0.01% | 3750 |
|
|
2018
Q4 | $761K | Buy |
4,342
+3,336
| +332% | +$666K | ﹤0.01% | 2728 |
|
|
2018
Q3 | $228K | Sell |
1,006
-4,092
| -80% | -$662K | ﹤0.01% | 3588 |
|
|
2018
Q2 | $772K | Buy |
+5,098
| New | +$926K | ﹤0.01% | 2970 |
|
|
2018
Q1 | – | Sell |
-18,789
| Closed | -$4M | – | 3695 |
|
|
2017
Q4 | $4M | Sell |
18,789
-9,843
| -34% | -$2.11M | 0.01% | 1866 |
|
|
2017
Q3 | $6.14M | Buy |
28,632
+5,316
| +23% | +$1.04M | 0.01% | 1550 |
|
|
2017
Q2 | $4.41M | Buy |
23,316
+1,587
| +7% | +$311K | 0.01% | 1590 |
|
|
2017
Q1 | $5.38M | Sell |
21,729
-2,576
| -11% | -$632K | 0.01% | 1420 |
|
|
2016
Q4 | $6.16M | Buy |
+24,305
| New | +$5.57M | 0.01% | 1191 |
|
|
2016
Q1 | – | Sell |
-374
| Closed | -$19K | – | 3315 |
|
|
2015
Q4 | $19K | Sell |
374
-433
| -54% | -$22.1K | ﹤0.01% | 3344 |
|
|
2015
Q3 | $38K | Buy |
+807
| New | +$53.7K | ﹤0.01% | 3368 |
|
Other funds holding CRBP
CAM
O
VCM
PM
DP
SCM
AC
Millennium Management's CRBP Position: Q1 2026 in Review
Millennium Management increased its Corbus Pharmaceuticals (CRBP) stake by 191% in Q1 2026, buying an estimated $596K and bringing the position to 107,800 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4385.
Millennium Management first reported a position in CRBP in Q3 2015 and has held it in 30 quarters since. The position peaked at $12.7M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.
- Millennium Management held 107,800 shares of Corbus Pharmaceuticals worth $1.01M as of Q1 2026.
- Millennium Management bought 70,735 Corbus Pharmaceuticals shares in Q1 2026, an estimated $596K.
- Corbus Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4385 holding.
- Millennium Management first reported a position in Corbus Pharmaceuticals in Q3 2015 and has held it in 30 quarters since.
- Millennium Management's Corbus Pharmaceuticals position peaked at $12.7M in Q1 2024.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.